The core Dravet syndrome phenotype
- PMID: 21463272
- DOI: 10.1111/j.1528-1167.2011.02994.x
The core Dravet syndrome phenotype
Abstract
Dravet syndrome was described in 1978 by Dravet (1978) under the name of severe myoclonic epilepsy in infancy (SMEI). The characteristics of the syndrome were confirmed and further delineated by other authors over the years. According to the semiologic features, two forms have been individualized: (1) the typical, core, SMEI; and (2) the borderline form, SMEIB, in which the myoclonic component is absent or subtle. Clinical manifestations at the onset, at the steady state, and during the course of the disease are analyzed in detail for the typical Dravet syndrome, and the differential diagnosis is discussed. Onset in the first year of life by febrile or afebrile clonic and tonic-clonic, generalized, and unilateral seizures, often prolonged, in an apparently normal infant is the first symptom, suggesting the diagnosis. Later on, multiple seizure types, mainly myoclonic, atypical absences, and focal seizures appear, as well as a slowing of developmental and cognitive skills, and the appearance of behavioral disorders. Mutation screening for the SCN1A gene confirms the diagnosis in 70-80% of patients. All seizure types are pharmacoresistent, but a trend toward less severe epilepsy and cognitive impairment is usually observed after the age of 5 years.
Wiley Periodicals, Inc. © 2011 International League Against Epilepsy.
Similar articles
-
Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies.Epilepsy Res. 2006 Aug;70 Suppl 1:S223-30. doi: 10.1016/j.eplepsyres.2006.01.019. Epub 2006 Jun 27. Epilepsy Res. 2006. PMID: 16806826 Review.
-
[Clinical and genetic diagnosis of Dravet syndrome: report of 20 cases].Ideggyogy Sz. 2008 Nov 30;61(11-12):402-8. Ideggyogy Sz. 2008. PMID: 19070316 Hungarian.
-
Dravet syndrome: from electroclinical characteristics to molecular biology.Epilepsia. 2009 Sep;50 Suppl 8:3-9. doi: 10.1111/j.1528-1167.2009.02228.x. Epilepsia. 2009. PMID: 19702726
-
Dravet syndrome history.Dev Med Child Neurol. 2011 Apr;53 Suppl 2:1-6. doi: 10.1111/j.1469-8749.2011.03964.x. Dev Med Child Neurol. 2011. PMID: 21504424 Review.
-
Borderline Dravet syndrome: a useful diagnostic category?Epilepsia. 2011 Apr;52 Suppl 2:10-2. doi: 10.1111/j.1528-1167.2011.02995.x. Epilepsia. 2011. PMID: 21463273 Review.
Cited by
-
Non-psychotropic phytocannabinoid interactions with voltage-gated sodium channels: An update on cannabidiol and cannabigerol.Front Physiol. 2022 Nov 10;13:1066455. doi: 10.3389/fphys.2022.1066455. eCollection 2022. Front Physiol. 2022. PMID: 36439273 Free PMC article. Review.
-
Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy in Children-A Literature Review.J Clin Med. 2024 Jan 29;13(3):780. doi: 10.3390/jcm13030780. J Clin Med. 2024. PMID: 38337474 Free PMC article. Review.
-
Fenfluramine HCl (Fintepla® ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study.Epilepsia. 2020 Nov;61(11):2396-2404. doi: 10.1111/epi.16722. Epub 2020 Oct 19. Epilepsia. 2020. PMID: 33078386 Free PMC article. Clinical Trial.
-
Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.Eur J Neurol. 2017 Feb;24(2):309-314. doi: 10.1111/ene.13195. Epub 2016 Oct 28. Eur J Neurol. 2017. PMID: 27790834 Free PMC article.
-
Brain expression profiles of two SCN1A antisense RNAs in children and adolescents with epilepsy.Transl Neurosci. 2024 Jan 23;15(1):20220330. doi: 10.1515/tnsci-2022-0330. eCollection 2024 Jan 1. Transl Neurosci. 2024. PMID: 38283997 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
